Expression of estrogen receptor exon 5 splicing variant (ER E5SV) mRNA in gynaecological cancers

Journal of Steroid Biochemistry and Molecular Biology

Volumn 60, Issue 1-2, 1997, Pages 25-30

  Fujimoto, Jiro ^a   Ichigo, Satoshi ^a   Hirose, Reiko ^a   Hori, Masashi ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM; EXON; FEMALE; GENE EXPRESSION; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; OVARY; RNA ANALYSIS; UTERINE CERVIX;

ADULT; AGED; CERVIX UTERI; ENDOMETRIUM; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RNA SPLICING; RNA, MESSENGER; UTERINE NEOPLASMS;

EID: 0030926163     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00168-9     Document Type: Article

References (32)

1. Clark J. H., Schrader W. T. and O'Malley B. W.: Mechanism of action of steroid hormone. In Williams Textbook of Endocrinology, 8th edn (Edited by Wilson J. D. and Foster D. W.). W. B. Saunders, Philadelphia (1992) pp. 35-90.
2. Lippman M. E. and Swain S. M.: Endocrine-responsive cancers of human. In Williams Textbook of Endocrinology, 8th edn (Edited by Wilson J. D. and Foster D. W.). W. B. Saunders, Philadelphia (1992) pp. 1577-1597.
3. Fujimoto J., Hori M., Ichigo S., Morishita S. and Tamaya T.: Estrogen activates migration potential of endometrial cancer cells through basement membrane. Tumor Biol. 17 (1996) 48-57.
4. Fujimoto J., Hori M., Ichigo S., Morishita S. and Tamaya T.: Estrogen activates invasiveness of endometrial cancer cells to the interstitium. Invas. Metast. 15 (1995) 135-143.
5. Fujimoto J., Fujita H., Hosoda S. and Okada H.: Effect of medroxyprogesterone acetate on secondary spreading of endometrial cancer. Invas. Metast. 9 (1989) 209-215.
6. Fujimoto J., Hosoda S., Fujita H. and Okada H.: Inhibition of tumor angiogenesis activity by medroxyprogesterone acetate in gynecologic malignant tumors. Invas. Metast. 9 (1989) 269-277.
7. Jikihara H., Terada N., Yamamoto R., Nishikawa Y., Tanizawa O., Matsumoto K. and Terakawa N.: Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. Am. J. Obstet. Gynecol. 167 (1992) 207-211.
8. Karnik P. S., Kulkarrii S., Liu X. P., Budd G. T. and Bukowski R. M.: Estrogen receptor mutation in tamoxifen-resistant breast cancer. Cancer Res. 54 (1994) 349-353.
9. Fujimoto J., Hori M., Ichigo S., Nishigaki M., Itoh T. and Tamaya T.: Expression of aberrant estrogen receptor mRNA in endometrial cancers in comparison with normal endometria. Horm. Res. 42 (1994) 116-119.
10. Lehrer S., Sanchez M., Song H. K., Dalton J., Levine E., Savoretti P., Thung S. and Schachter B.: Oestrogen receptor B-region polymorphism and spontaneous abortion in women with breast cancer. Lancet 335 (1990) 622-624.
11. Taylor J. A., Wilcox A. J., Bowes W. A., Lui E. T. and You M.: Risk of miscarriage and a common variant of the estrogen receptor gene. Am. J. Epidemiol. 137 (1993) 1361-1364.
12. Schmutzler R. K., Sanchez M., Lehrer S., Chaparro C.-A., Phillips C., Rabin J. and Schachter B.: Incidence of an estrogen receptor polymorphism in breast cancer patients. Breast Cancer Res. Treat. 19 (1994) 111-117.
13. Wang Y. and Miksicek R. J.: Identification of a dominant negative form of the human estrogen receptor. Molec. Endocr. 5 (1991) 1707-1715.
14. R-1 compared to the parental MCF-7 cell line. Molec. Cell Endocr. 109 (1995) 197-207.
15. Miksicek R. J., Lei Y. and Wang Y.: Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Res. Treat. 26 (1993) 163-174.
16. Skipper J. K., Young L. J., Bergeron J. M., Tetzlaff M. T., Osborn C. T. and Crews D.: Identification of an iso form of the estrogen receptor messenger RNA lacking exon four and present in the brain. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 7172-7175.
17. Koehorst S. G. A., Jacob H. M., Thijssen J. H. H. and Blankenstein M. A.: Wild type alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF-7 breast cancer cells. J. Steroid Biochem. Molec. Biol. 45 (1993) 227-233.
18. Koehorst S. G. A., Cox J. J., Donker G H., Lopes da Silva S., Burbach J. P. H., Thijssen J. H. H. and Blankenstein M. A.: Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. Molec. Cell Endocr. 101 (1994) 237-245.
19. Fuqua S. A. W., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonell D. P., Nawaz Z., O'Malley B. W. and McGuire W. L.: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51 (1991) 105-109.
20. Daffada A. A. I., Johnston S. R. D., Smith I. E., Detre S., King N. and Dowsett M.: Exon 5 deletion variant estrogen receotor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res. 55 (1995) 288-293.
21. Fuqua S. A. W., Fitzgerald S. D., Allred D. C., Elledge R. M., Nawaz Z., McDonell D. P., O'Malley B. W., Greene G. L. McGuire W. L.: Inhibition of estrogen receptor action by a naturally occurring variant in humam breast tumors. Cancer Res. 52 (1992) 483-486.
22. FIGO News: Int. J. Gynecol. Obstet., 28 (1989) 189-193.
23. Chomczynski P. and Sacchi N.: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analyt. Biochem. 162 (1987) 156-159.
24. Castles C. G., Fuqua S. A. W., Klotz D. M. and Hill S. M.: Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 53 (1993) 5934-5939.
25. Tora L., White J. H., Brou C., Tasset D., Webster N., Scheer E. and Chambon P.: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59 (1989) 477-487.
26. Metzger D., White J. H. and Chambon P.: The human oestrogen receptor functions in yeast. Nature 74 (1988) 31-36.
27. Fuqua S. A. W., Allred D. C. and Auchus R. J.: Expression of estrogen receptor variants. J. Cell Biochem. 17G (1993) 194-197.
28. Rea D. and Parker M. G.: Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells. Cancer Res. 56 (1996) 1556-1563.
29. Fuqua S. A. W. and Wolf D. M.: Molecular aspect of estrogen receptor variants in breast cancer. Breast Cancer Res. 35 (1995) 233-241.
30. Fuqua S. A. W., Wiltschke C., Castles C., Wolf D. M. and Allred D. C.: A role for estrogen-receptor variants in endocrine resistance. Endocr. Related Cancer 2 (1995) 19-25.
31. Gotteland M., Desauty G., Delarue J. C., Liu L. and May E.: Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues. Molec. Cell. Endocr. 112 (1995) 1-13.
32. Pfeffer U., Fecarotta E. and Vidali G.: Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res. 55 (1995) 2158-2165.